← ANALYST RATINGS · TIPRANKS
Evommune, Inc. (EVMN): analyst forecast and price target
Price targets and ratings of
Analyst consensus
Strong Buy10 Buy3 Hold0 Sell
Ratings of 13 analysts in the last 3 months12-month forecast
$22.40+333.3% upside
Based on 13 price targets given in the last 3 months, the average target is $22.40, the highest $30.00, the lowest $8.00. The average is +333.3% from the last price of $5.17.
Highest target $30.00
Average target $22.40
Lowest target $8.00
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.50 → $6.00+9.1% | Hold | +16.1% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $5.50 → $6.00+9.1% | Hold | +16.1% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $5.50 → $6.00+9.1% | Hold | +16.1% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $5.50 → $6.00+9.1% | Hold | +16.1% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.00 → $5.50−8.3% | Hold | +6.4% | Reiterated | 15.10.26on TipRanks 18:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.00 → $5.50−8.3% | Hold | +6.4% | Reiterated | 15.10.26on TipRanks 18:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $6.00 → $5.50−8.3% | Hold | +6.4% | Reiterated | 15.10.26on TipRanks 18:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.00 → $5.50−8.3% | Hold | +6.4% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.00 → $5.50−8.3% | Hold | +6.4% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.50 → $6.00−7.7% | Hold | +16.1% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| Name not given | — | $8.00 | Hold | +54.7% | Initiated | 12.10.26on TipRanks 06:05 | −3.1%next day −2.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.00 → $6.00−14.3% | Hold | +16.1% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $6.50−13.3% | Hold | +25.7% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.00 → $6.00−14.3% | Hold | +16.1% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.00 → $6.00−14.3% | Hold | +16.1% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.00 → $6.00−14.3% | Hold | +16.1% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.00 → $6.00−14.3% | Hold | +16.1% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | — | Hold | — | Reiterated | 05.10.26on TipRanks 06:50 | −4.6%next day −1.2% · 5 days −9.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $7.00−12.5% | Hold | +35.4% | Reiterated | 02.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.50 → $7.50−11.8% | Hold | +45.1% | Reiterated | 02.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $7.00−12.5% | Hold | +35.4% | Reiterated | 02.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 → $7.00−12.5% | Hold | +35.4% | Reiterated | 02.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.50 → $7.00−17.6% | Hold | +35.4% | Reiterated | 02.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 → $7.00−12.5% | Hold | +35.4% | Reiterated | 02.10.26on TipRanks 06:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $9.50 → $8.00−15.8% | Hold | +54.7% | Reiterated | 01.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $9.50 → $8.50−10.5% | Hold | +64.4% | Reiterated | 01.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $9.50 → $8.00−15.8% | Hold | +54.7% | Reiterated | 01.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $9.00 → $8.00−11.1% | Hold | +54.7% | Reiterated | 01.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $9.50 → $8.50−10.5% | Hold | +64.4% | Reiterated | 01.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $9.50 → $8.00−15.8% | Hold | +54.7% | Reiterated | 01.10.26on TipRanks 10:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $10.00 → $9.50−5.0% | Hold | +83.8% | Reiterated | 24.09.26on TipRanks Sep 23 21:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $10.00 → $9.50−5.0% | Hold | +83.8% | Reiterated | 24.09.26on TipRanks Sep 23 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.00 → $9.50−5.0% | Hold | +83.8% | Reiterated | 24.09.26on TipRanks Sep 23 21:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.00 → $9.00−10.0% | Hold | +74.1% | Reiterated | 24.09.26on TipRanks Sep 23 21:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $10.00 → $9.50−5.0% | Hold | +83.8% | Reiterated | 24.09.26on TipRanks Sep 23 21:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $10.00 → $9.50−5.0% | Hold | +83.8% | Reiterated | 24.09.26on TipRanks Sep 23 21:05 | — | |
| Prakhar Agrawal★★★★★★★★★★#1817 · hits 40% · avg +16.0% | Cantor Fitzgerald | — | Buy | — | Reiterated | 17.09.26on TipRanks Sep 18 07:45 | −1.1%next day +2.9% · 5 days −6.9% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $28.00 → $22.00−21.4% | Buy | +325.5% | Assigned | 10.09.26on TipRanks Sep 9 08:35 | −16.7%next day −2.0% · 5 days −12.5% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $28.00 → $23.00−17.9% | Buy | +344.9% | Reiterated | 09.09.26on TipRanks 19:55 | −2.0%next day −1.0% · 5 days −11.9% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $30.00 | Buy | +480.3% | Reiterated | 09.09.26on TipRanks 10:35 | −16.7%next day −2.0% · 5 days −12.5% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $28.00 | Buy | +441.6% | Reiterated | 09.09.26on TipRanks 09:35 | −16.7%next day −2.0% · 5 days −12.5% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $18.00 | Buy | +248.2% | Reiterated | 09.09.26on TipRanks 08:30 | −16.7%next day −2.0% · 5 days −12.5% | ↗ |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $26.00 | Buy | +402.9% | Reiterated | 09.09.26on TipRanks 07:50 | −16.7%next day −2.0% · 5 days −12.5% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | — | Hold | — | Reiterated | 09.09.26on TipRanks 06:30 | −16.7%next day −2.0% · 5 days −12.5% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Hold | — | Reiterated | 09.09.26on TipRanks 05:30 | −16.7%next day −2.0% · 5 days −12.5% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $29.00 → $21.00−27.6% | Buy | +306.2% | Reiterated | 08.09.26on TipRanks Sep 9 07:30 | +7.2%next day −16.7% · 5 days −22.5% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $22.00 | Buy | +325.5% | Reiterated | 10.08.26on TipRanks 08:40 | 0.0%next day +1.3% · 5 days +1.3% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $26.00 | Buy | +402.9% | Assigned | 10.08.26on TipRanks 08:21 | 0.0%next day +1.3% · 5 days +1.3% | ↗ |
| Andreas Argyrides★★★★★★★★★★#1658 · hits 46% · avg +10.2% | Chardan Capital | $42.00 | Buy | +712.4% | Initiated | 23.01.26on TipRanks Jan 22 08:20 | −0.3%next day −0.1% · 5 days +13.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Evommune, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $24.00 at a price of $8.26 (+190.6%); now: $22.40 at $5.17 (+333.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 14 | 12 | 11 | 14 | 12 |
| Buy | 6 | 5 | 3 | 1 | 1 | 1 |
| Hold | 0 | 2 | 2 | 5 | 5 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.12.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.83 (from $-1.02 to $-0.67). Last quarter: $-0.89.
Best top-analyst consensus in the sector · General
About Evommune, Inc.
- CEO: Luis C. Pena
- Employees: 48
- 1841 Page Mill Road, Palo Alto, CA, 94304, US
- www.evommune.com
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Data from the stock’s TipRanks forecast page, read 55 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗